MeiraGTx’s (MGTX) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of MeiraGTx (NASDAQ:MGTX) in a report issued on Monday morning,Benzinga reports. Chardan Capital currently has a $36.00 price target on the stock.

Separately, Royal Bank of Canada lifted their price target on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th.

MeiraGTx Trading Up 1.7 %

Shares of MeiraGTx stock opened at $5.92 on Monday. The company’s fifty day simple moving average is $5.28 and its 200-day simple moving average is $4.82. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86. The company has a market cap of $462.65 million, a price-to-earnings ratio of -4.89 and a beta of 1.24. MeiraGTx has a 1 year low of $3.85 and a 1 year high of $7.60.

Institutional Investors Weigh In On MeiraGTx

Institutional investors and hedge funds have recently made changes to their positions in the company. Knoll Capital Management LLC bought a new position in shares of MeiraGTx in the third quarter valued at approximately $5,212,000. Erste Asset Management GmbH acquired a new position in MeiraGTx in the third quarter worth $2,795,000. Garden State Investment Advisory Services LLC bought a new stake in shares of MeiraGTx during the third quarter worth $1,636,000. Privium Fund Management B.V. increased its stake in shares of MeiraGTx by 70.0% in the second quarter. Privium Fund Management B.V. now owns 203,960 shares of the company’s stock valued at $804,000 after buying an additional 83,975 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of MeiraGTx by 107.1% in the third quarter. Barclays PLC now owns 147,827 shares of the company’s stock valued at $618,000 after buying an additional 76,437 shares during the last quarter. Institutional investors and hedge funds own 67.48% of the company’s stock.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.